September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Pharmacological normalization of the complement system dysregulation in the animal model of enhanced lipofuscin formation.
Author Affiliations & Notes
  • Konstantin Petrukhin
    Department of Ophthalmology, Columbia University, New York, New York, United States
  • Boglarka Racz
    Department of Ophthalmology, Columbia University, New York, New York, United States
  • Footnotes
    Commercial Relationships   Konstantin Petrukhin, iCura Vision (I), The Trustees of Columbia University in the City of New York (P); Boglarka Racz, None
  • Footnotes
    Support  This study was supported by NIH Grants U01 NS074476 (to K.P.), P30 EY019007 (Core Support for Vision Research), and unrestricted funds from Research to Prevent Blindness (New York, NY) to the Department of Ophthalmology, Columbia University.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 277. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Konstantin Petrukhin, Boglarka Racz; Pharmacological normalization of the complement system dysregulation in the animal model of enhanced lipofuscin formation.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):277.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Complement system dysregulation in the retina plays a critical role in pathogenesis of dry AMD. Normalization of the complement system dysregulation may represent a treatment strategy for dry AMD and, potentially, Stargardt disease. It has been recently reported that enhanced accumulation of lipofuscin in the eyes of abca4-/- mice is associated with complement activation. We developed a novel cyclopentyl fused pyrrolidine Retinol-Binding Protein 4 (RBP4) antagonist as a potential drug candidate for Stargardt disease and dry AMD. The compound partially restricts retinol supply to the RPE and induces drastic inhibition of bisretinoid synthesis in the abca4-/- model. Here we report the data on normalization of the complement system dysregulation by this drug candidate in the abca4-/- mouse model of enhanced lipofuscin formation

Methods : Abca4-/- mice were treated with the compound formulated into a chow at the dose that induces ~80% of serum RBP4 reduction. Two control groups of vehicle-treated abca4-/- and abca4+/+ animals were included in the study. Compound dosing was conducted for 3 months. Immunoblot analysis of retinal extracts as well as immunofluorescence analysis of retinal sections were conducted in the treatment and control groups to determine levels of expression for C3/C3b, CFH, CFD, MCP-1 as well as for C-reactive protein

Results : Significant dysregulation of C3/C3b, CFH, CFD and C-reactive protein was observed in eyes of the vehicle-treated abca4-/- mice in comparison to the untreated abca4+/+ controls. Expression of C3/C3b, CFD and C-reactive protein was significantly increased in the abca4-/- mice while expression of CFH was significantly decreased. There was no difference in the MCP-1 expression between untreated abca4-/- and abca4+/+ animals. Compound dosing normalized the expression of all dysregulated complement system components in the treatment group

Conclusions : Administration of the optimized RPB4 antagonist normalized complement system dysregulation in eyes of the abca4-/- mice. The effect seems to relate to the ability of the drug candidate to drastically inhibit bisretinoid synthesis in this animal model. In addition, the drug candidate may directly interfere with the retinol-independent pro-inflammatory signaling function of RBP4 that was ascribed to this adipokine in alternative experimental systems

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×